With the deepening of research, it has been discovered that PARP inhibitors were not only beneficial for patients with ovarian cancer with mutation in BRCA 1/2 and HRD, but also for patients with no mutation possibly in ovarian cancer [10]. This evidence concerns the gene PARP1 and ovarian carcinoma.